Management of Superficial Thrombophlebitis

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2011

Conditions
Superficial ThrombophlebitisUpper Extremity Superficial ThrombophlebitisLower Extremity Superficial Thrombophlebitis
Interventions
DRUG

Dalteparin sodium injection

Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.

Trial Locations (2)

73104

Department of Veterans Affairs Medical Center, Oklahoma City

University of Oklahoma Health Science Center, Oklahoma City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Oklahoma

OTHER